
Myriad Genetics Inc (MYGN) - Product Pipeline Analysis, 2024 Update
Description
Myriad Genetics Inc (MYGN) - Product Pipeline Analysis, 2024 Update
Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Myriad Genetics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
75 Pages
- Myriad Genetics Inc Company Overview
- Myriad Genetics Inc Company Snapshot
- Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Myriad Genetics Inc – Pipeline Analysis Overview
- Business Description
- Myriad Genetics Inc - Key Facts
- Myriad Genetics Inc - Major Products and Services
- Myriad Genetics Inc Pipeline Products by Development Stage
- Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
- Myriad Genetics Inc Pipeline Products Overview
- ChemoPredict Test
- ChemoPredict Test Product Overview
- Companion Diagnostic Test - Measurable Residual Disease (MRD)
- Companion Diagnostic Test - Measurable Residual Disease (MRD) Product Overview
- Diagnostic Assay - HER2+/TNBC-Breast Cancer
- Diagnostic Assay - HER2+/TNBC-Breast Cancer Product Overview
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis
- Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis Product Overview
- Diagnostic Assay - Lung Cancer
- Diagnostic Assay - Lung Cancer Product Overview
- Diagnostic Assay - Melanoma
- Diagnostic Assay - Melanoma Product Overview
- Diagnostic Assay - Prostate Cancer
- Diagnostic Assay - Prostate Cancer Product Overview
- Diagnostic Test - Colon Cancer
- Diagnostic Test - Colon Cancer Product Overview
- Diagnostic Test - Kidney Damage
- Diagnostic Test - Kidney Damage Product Overview
- FirstGene Multiple Prenatal Screen
- FirstGene Multiple Prenatal Screen Product Overview
- Foresight Universal Plus
- Foresight Universal Plus Product Overview
- GeneSight Postpartum Depression Test
- GeneSight Postpartum Depression Test Product Overview
- Genetic Risk Score Test
- Genetic Risk Score Test Product Overview
- HRD Companion Diagnostic Test - Breast Cancer
- HRD Companion Diagnostic Test - Breast Cancer Product Overview
- Kidney Transplant Rejection Test
- Kidney Transplant Rejection Test Product Overview
- Lab Developed Test - BRCA Cancer
- Lab Developed Test - BRCA Cancer Product Overview
- Multi-Biomarker Test - Ankylosing Spondylitis
- Multi-Biomarker Test - Ankylosing Spondylitis Product Overview
- Multi-Biomarker Test - Autoimmune Diseases
- Multi-Biomarker Test - Autoimmune Diseases Product Overview
- Multi-Biomarker Test - Inflammatory Diseases
- Multi-Biomarker Test - Inflammatory Diseases Product Overview
- Multi-Biomarker Test - Psoriatic Arthritis
- Multi-Biomarker Test - Psoriatic Arthritis Product Overview
- Multi-Biomarker Test - Systemic Lupus Erythematosus
- Multi-Biomarker Test - Systemic Lupus Erythematosus Product Overview
- myChoice CDx Test - Multiple Cancer
- myChoice CDx Test - Multiple Cancer Product Overview
- myChoice CDx Test - Multiple Cancer Clinical Trial
- myChoice Diabetes
- myChoice Diabetes Product Overview
- myChoice HRD (PARP) - Talazoparib
- myChoice HRD (PARP) - Talazoparib Product Overview
- myPath BiPolar
- myPath BiPolar Product Overview
- myPath Endometriosis
- myPath Endometriosis Product Overview
- myPath Pancreatic Cancer
- myPath Pancreatic Cancer Product Overview
- myPath Prostate Cancer
- myPath Prostate Cancer Product Overview
- myPath Psoriatic Arthritis
- myPath Psoriatic Arthritis Product Overview
- myPlan Renal Cancer Test
- myPlan Renal Cancer Test Product Overview
- myRisk Schizophrenia
- myRisk Schizophrenia Product Overview
- Precise Liquid Bx MRD
- Precise Liquid Bx MRD Product Overview
- Prognostic Test - Bladder Cancer
- Prognostic Test - Bladder Cancer Product Overview
- Prolaris Post-Radical Prostatectomy
- Prolaris Post-Radical Prostatectomy Product Overview
- SanoPredict
- SanoPredict Product Overview
- Tumor BRACAnalysis CDx - Veliparib
- Tumor BRACAnalysis CDx - Veliparib Product Overview
- VeriPsych Test - Bipolar Disorder
- VeriPsych Test - Bipolar Disorder Product Overview
- Whole Exome Companion Diagnostic Test
- Whole Exome Companion Diagnostic Test Product Overview
- Whole Exome Laboratory Developed Test
- Whole Exome Laboratory Developed Test Product Overview
- Myriad Genetics Inc - Key Competitors
- Myriad Genetics Inc - Key Employees
- Myriad Genetics Inc - Key Employee Biographies
- Myriad Genetics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Myriad Genetics Inc, Recent Developments
- May 16, 2024: New Study Published in JCO Precision Oncology Shows Myriad Genetics’ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
- May 07, 2024: Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
- May 02, 2024: Yourbio Health Congratulates Myriad Genetics on One Million Sales of Sneakpeek Tests Enabled by Yourbio’s Virtually Painless Tap Technology
- Apr 09, 2024: Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
- Mar 21, 2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Mar 20, 2024: Myriad Genetics Announces Patent Granted for SneakPeek Snap Device
- Mar 08, 2024: Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- Feb 21, 2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Jan 14, 2024: Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Myriad Genetics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Table 2: Myriad Genetics Inc Pipeline Products by Equipment Type
- Table 3: Myriad Genetics Inc Pipeline Products by Indication
- Table 4: Myriad Genetics Inc, Key Facts
- Table 5: Myriad Genetics Inc, Major Products and Services
- Table 6: Myriad Genetics Inc Number of Pipeline Products by Development Stage
- Table 7: Myriad Genetics Inc Pipeline Products Summary by Development Stage
- Table 8: Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
- Table 9: Myriad Genetics Inc Ongoing Clinical Trials Summary
- Table 10: ChemoPredict Test - Product Status
- Table 11: ChemoPredict Test - Product Description
- Table 12: Companion Diagnostic Test - Measurable Residual Disease (MRD) - Product Status
- Table 13: Companion Diagnostic Test - Measurable Residual Disease (MRD) - Product Description
- Table 14: Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Status
- Table 15: Diagnostic Assay - HER2+/TNBC-Breast Cancer - Product Description
- Table 16: Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Status
- Table 17: Diagnostic Assay - Juvenile Idiopathic Rheumatoid Arthritis - Product Description
- Table 18: Diagnostic Assay - Lung Cancer - Product Status
- Table 19: Diagnostic Assay - Lung Cancer - Product Description
- Table 20: Diagnostic Assay - Melanoma - Product Status
- Table 21: Diagnostic Assay - Melanoma - Product Description
- Table 22: Diagnostic Assay - Prostate Cancer - Product Status
- Table 23: Diagnostic Assay - Prostate Cancer - Product Description
- Table 24: Diagnostic Test - Colon Cancer - Product Status
- Table 25: Diagnostic Test - Colon Cancer - Product Description
- Table 26: Diagnostic Test - Kidney Damage - Product Status
- Table 27: Diagnostic Test - Kidney Damage - Product Description
- Table 28: FirstGene Multiple Prenatal Screen - Product Status
- Table 29: FirstGene Multiple Prenatal Screen - Product Description
- Table 30: Foresight Universal Plus - Product Status
- Table 31: Foresight Universal Plus - Product Description
- Table 32: GeneSight Postpartum Depression Test - Product Status
- Table 33: GeneSight Postpartum Depression Test - Product Description
- Table 34: Genetic Risk Score Test - Product Status
- Table 35: Genetic Risk Score Test - Product Description
- Table 36: HRD Companion Diagnostic Test - Breast Cancer - Product Status
- Table 37: HRD Companion Diagnostic Test - Breast Cancer - Product Description
- Table 38: Kidney Transplant Rejection Test - Product Status
- Table 39: Kidney Transplant Rejection Test - Product Description
- Table 40: Lab Developed Test - BRCA Cancer - Product Status
- Table 41: Lab Developed Test - BRCA Cancer - Product Description
- Table 42: Multi-Biomarker Test - Ankylosing Spondylitis - Product Status
- Table 43: Multi-Biomarker Test - Ankylosing Spondylitis - Product Description
- Table 44: Multi-Biomarker Test - Autoimmune Diseases - Product Status
- Table 45: Multi-Biomarker Test - Autoimmune Diseases - Product Description
- Table 46: Multi-Biomarker Test - Inflammatory Diseases - Product Status
- Table 47: Multi-Biomarker Test - Inflammatory Diseases - Product Description
- Table 48: Multi-Biomarker Test - Psoriatic Arthritis - Product Status
- Table 49: Multi-Biomarker Test - Psoriatic Arthritis - Product Description
- Table 50: Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Status
- Table 51: Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Description
- Table 52: myChoice CDx Test - Multiple Cancer - Product Status
- Table 53: myChoice CDx Test - Multiple Cancer - Product Description
- Table 54: myChoice CDx Test - Multiple Cancer - A Phase III Randomised, Double-blind, Placebo-controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
- Table 55: myChoice Diabetes - Product Status
- Table 56: myChoice Diabetes - Product Description
- Table 57: myChoice HRD (PARP) - Talazoparib - Product Status
- Table 58: myChoice HRD (PARP) - Talazoparib - Product Description
- Table 59: myPath BiPolar - Product Status
- Table 60: myPath BiPolar - Product Description
- Table 61: myPath Endometriosis - Product Status
- Table 62: myPath Endometriosis - Product Description
- Table 63: myPath Pancreatic Cancer - Product Status
- Table 64: myPath Pancreatic Cancer - Product Description
- Table 65: myPath Prostate Cancer - Product Status
- Table 66: myPath Prostate Cancer - Product Description
- Table 67: myPath Psoriatic Arthritis - Product Status
- Table 68: myPath Psoriatic Arthritis - Product Description
- Table 69: myPlan Renal Cancer Test - Product Status
- Table 70: myPlan Renal Cancer Test - Product Description
- Table 71: myRisk Schizophrenia - Product Status
- Table 72: myRisk Schizophrenia - Product Description
- Table 73: Precise Liquid Bx MRD - Product Status
- Table 74: Precise Liquid Bx MRD - Product Description
- Table 75: Prognostic Test - Bladder Cancer - Product Status
- Table 76: Prognostic Test - Bladder Cancer - Product Description
- Table 77: Prolaris Post-Radical Prostatectomy - Product Status
- Table 78: Prolaris Post-Radical Prostatectomy - Product Description
- Table 79: SanoPredict - Product Status
- Table 80: SanoPredict - Product Description
- Table 81: Tumor BRACAnalysis CDx - Veliparib - Product Status
- Table 82: Tumor BRACAnalysis CDx - Veliparib - Product Description
- Table 83: VeriPsych Test - Bipolar Disorder - Product Status
- Table 84: VeriPsych Test - Bipolar Disorder - Product Description
- Table 85: Whole Exome Companion Diagnostic Test - Product Status
- Table 86: Whole Exome Companion Diagnostic Test - Product Description
- Table 87: Whole Exome Laboratory Developed Test - Product Status
- Table 88: Whole Exome Laboratory Developed Test - Product Description
- Table 89: Myriad Genetics Inc, Key Employees
- Table 90: Myriad Genetics Inc, Key Employee Biographies
- Table 91: Myriad Genetics Inc, Subsidiaries
- Table 92: Glossary
- List of Figures
- Figure 1: Myriad Genetics Inc Pipeline Products by Equipment Type
- Figure 2: Myriad Genetics Inc Pipeline Products by Development Stage
- Figure 3: Myriad Genetics Inc Ongoing Clinical Trials by Trial Status
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.